Daiichi Sankyo Eyes U.S. Expansion With Major Sales Force Boost
This article was originally published in PharmAsia News
Daiichi Sankyo plans to more than double its U.S. sales force by 2010 in an effort to further expand outside of its home Japanese market, the firm announced Feb. 14
You may also be interested in...
If approved, WelChol would be the first LDL-lowering therapy also approved for improving glycemic control.
Combination of olmesartan and amlodipine can be used alone or in conjunction with other antihypertensives, firm says.
Merger will allow the partners to increase R&D in cardiovascular, antibacterial, glucose metabolic, bone disorder, immune disorder and anti-allergy categories. As a single entity, Daiichi and Sankyo expect to increase their combined 2,200-person global sales force.